At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Standard of Care Chemotherapy, and 1 other intervention for Non-Small Cell Lung Cancer and Solid Tumor. Completed, enrolled 46 participants across 7 sites.
Detailed Summary
This is a Phase II, two part trial (A and B), open label study of Atezolizumab and tiragolumab, or atezolizumab combined with SOC chemotherapy in patients with NSCLC or advanced solid tumors that have had prior treatment with a PD-1 inhibitor (e.g. nivolumab or pembrolizumab).
Study Details
Timeline
Interventions
Atezolizumab at a flat dose of 1200 mg IV every 3 weeks
Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
Tiragolumab at a flat dose of 600 mg IV every 3 weeks